NASDAQ$NBP
NovaBridge Biosciences · Q1 2023 earnings
Q1 2023 earnings · · After market close · Investor relations
Reports awaiting report
I-Mab hasn't published Q1 2023 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.
Most recent report Q4 2022
- Revenue
- -$222M
- EPS
- -$13.21
Year-ago · Q1 2022 Q1 2022
- Revenue
- $5.44M
- EPS
- -$1.24
Revenue & EPS history
I-Mab · Revenue · Quarterly
-$222M
Q4 2022-351.7%vs Q4 2021
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2023
+5.1%
Avg return
Earnings day
+4.3%
Avg return
5 days after
+9.7%
Avg return
30 days after
54%
7 / 13 earnings
Positive
+17.2%
Q2 2022
Best reaction
-7.7%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2023 | +0.0% | -1.1% | — | |
| Q4 2022 | -4.2% | -1.6% | +0.6% | |
| Q2 2021 | +17.2% | +34.6% | +13.3% | |
| Q2 2022 | +17.2% | +34.6% | +13.3% | |
| Q4 2021 | +7.0% | +7.1% | -35.6% | |
| Q1 2022 | +12.5% | +3.9% | -23.7% | |
| Q4 2020 | -6.9% | -3.6% | +25.8% | |
| Q3 2021 | -7.7% | -8.2% | -21.5% | |
| Q3 2020 | -7.7% | -8.2% | -21.5% | |
| Q2 2020 | -0.9% | -8.8% | -4.5% | |
| Q4 2017 | +13.2% | +2.4% | +56.8% | |
| Q4 2019 | +13.2% | +2.4% | +56.8% | |
| Q4 2018 | +13.2% | +2.4% | +56.8% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro